TY - JOUR
T1 - Análisis de la efectividad del tratamiento neoadyuvante al añadir docetaxel secuencial a fluorouracilo, epirrubicina y ciclofosfamida en pacientes con cáncer de marna avanzado
T2 - Resultados preliminares de respuesta tumoral
AU - Ramírez-Torres, Nicolás
AU - Moctezuma-Meza, Christian
AU - Asbun-Bojalil, Juan
AU - Valenzuela-Martínez, Larissa Antonieta
AU - Victoria-Ayala, Rosalia
AU - Ortiz-Rodríguez, Kenia
AU - Ayala-Anzures, María Eugenia
AU - Navarro-Muñoz, Fidel
AU - Castelazo-Rico, Germán
AU - Patlán-Pérez, Rosa María
AU - Tena-Alávez, Gilberto
AU - De La Vega, Horacio Astudillo
N1 - Publisher Copyright:
© 2015, Sociedad Mexicana de Oncología.
PY - 2015
Y1 - 2015
N2 - Objective: Retrospective study, designed to assess the effectiveness and tolerability of docetaxel sequential to epirubicin as neoadjuvant systemic therapy (NST) in women with locally advanced breast cancer (LABC). Patients and Methods: A total of 126 LABC-diagnosed patients were included (70 stage IIIA; 53 stage IIIB; 3 stage IIIC). The patients received FEC (500 mg/m2, 75 mg/m2, 500 mg/m2, respectively) every 3 weeks for 4 cycles, followed by docetaxel 75 mg/m2 every 3 weeks for 4 cycles. Surgery was performed at the end of the chemotherapy. Results: In the analysis of the 4FEC-4D scheme by groups, a significant increase in clinical complete response (cCR) was observed when docetaxel was added to preoperative FEC (Wilcoxon test, z = -2.35; P =.019). An objective response rate (ORR) of 78.5% (95% confidence interval [95% CI], 71.4 - 85.7) and pathological complete response (pCR) of 30.2% (95% CI, 22.2 - 38.2) were obtained. In the pCR group, tumors with stage IIIA lower nuclear grade and ER-positiveness showed higher response to NST (71.1%, 84.2% and 61.7%, respectively). The proportion of patients with negative lymph nodes was 51.6%. (95% CI: 42.9 - 60.3). The FEC regimen had more severe emetic effects, such as nausea (3.3%) and vomiting (2.1%). The docetaxel regimen produced severe toxicities, including myalgia (2.0%), fatigue (1.4%), and peripheral sensory neuropathy (0.4%). Conclusion: This study showed that the sequential addition of standard-dose docetaxel to FEC is highly active, feasible and well tolerated in patients with LABC.
AB - Objective: Retrospective study, designed to assess the effectiveness and tolerability of docetaxel sequential to epirubicin as neoadjuvant systemic therapy (NST) in women with locally advanced breast cancer (LABC). Patients and Methods: A total of 126 LABC-diagnosed patients were included (70 stage IIIA; 53 stage IIIB; 3 stage IIIC). The patients received FEC (500 mg/m2, 75 mg/m2, 500 mg/m2, respectively) every 3 weeks for 4 cycles, followed by docetaxel 75 mg/m2 every 3 weeks for 4 cycles. Surgery was performed at the end of the chemotherapy. Results: In the analysis of the 4FEC-4D scheme by groups, a significant increase in clinical complete response (cCR) was observed when docetaxel was added to preoperative FEC (Wilcoxon test, z = -2.35; P =.019). An objective response rate (ORR) of 78.5% (95% confidence interval [95% CI], 71.4 - 85.7) and pathological complete response (pCR) of 30.2% (95% CI, 22.2 - 38.2) were obtained. In the pCR group, tumors with stage IIIA lower nuclear grade and ER-positiveness showed higher response to NST (71.1%, 84.2% and 61.7%, respectively). The proportion of patients with negative lymph nodes was 51.6%. (95% CI: 42.9 - 60.3). The FEC regimen had more severe emetic effects, such as nausea (3.3%) and vomiting (2.1%). The docetaxel regimen produced severe toxicities, including myalgia (2.0%), fatigue (1.4%), and peripheral sensory neuropathy (0.4%). Conclusion: This study showed that the sequential addition of standard-dose docetaxel to FEC is highly active, feasible and well tolerated in patients with LABC.
KW - Locally advanced breast cancer
KW - Neoadjuvant systemic therapy
KW - Sequential docetaxel
UR - http://www.scopus.com/inward/record.url?scp=84943162983&partnerID=8YFLogxK
U2 - 10.1016/j.gamo.2015.06.002
DO - 10.1016/j.gamo.2015.06.002
M3 - Artículo
SN - 1665-9201
VL - 14
SP - 3
EP - 12
JO - Gaceta Mexicana de Oncologia
JF - Gaceta Mexicana de Oncologia
IS - 1
ER -